Subscribe to Entrepreneur for $5

The Zacks Analyst Blog Highlights: SOXL, TQQQ, CURE, FAS and RETL

The Zacks Analyst Blog Highlights: SOXL, TQQQ, CURE, FAS and RETL

This story originally appeared on Zacks

For Immediate Release

Chicago, IL – October 22, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. ETFs recently featured in the blog include: Direxion Daily Semiconductor Bull 3X Shares SOXL, ProShares UltraPro QQQ TQQQ, Direxion Daily Healthcare Bull 3x Shares CURE, Direxion Daily Financial Bull 3x Shares FAS and Direxion Daily Retail Bull 3x Shares RETL.

- Zacks

Here are highlights from Thursday’s Analyst Blog:

Best Leveraged ETF Areas of the Past Decade

In the past decade, we saw “the king of all bull markets.” The run was the longest ever. An easy money policy has been the main driver of this bull market. Though Wall Street’s record bull run ended on Mar 12, 2020 on COVID-induced selloffs, markets again shrugged off all worries and are hovering around all-time high levels.

Fed’s massive stimulus, record-bottom rates, fat fiscal stimulus in times of crisis, a divided Congress, a faster-than-expected rollout of coronavirus vaccines and chances of an antiviral treatment have been propelling the space.


Rising consumer spending on technology, a 5G boom, expectations of higher smartphone sales, rising demand for electric vehicles, the announcement of the phase-one U.S.-China trade deal and coronavirus-induced social distancing propelled the tech and semiconductor space.

Direxion Daily Semiconductor Bull 3X Shares – Up 7721.2%


The decade-long cheap money inflows and global economic improvement (before the virus outbreak) made growth stocks and the tech-heavy ETF winners last decade. The sector overall has been thriving on exponential growth in enterprise cloud computing, cyber security, remote communications, video gaming and e-commerce to online payments.

ProShares UltraPro QQQ – Up 8516.2%


Mergers and acquisitions, positive drug data and FDA approvals were the key catalysts for the space. A total of 378 novel drugs and 27 biosimilars were approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019. Oncology remains the top therapy area (25%), followed by infection (15%) and central nervous system disorders (11%).

Direxion Daily Healthcare Bull 3x Shares – Up 2427.9%


Rock-bottom rates boosted activities in both areas — household and corporates — thus favoring banking transactions. An upbeat stock market benefited the trading business of banks. The performance of the investment banking business has also been strong due to hefty IPO activities, and mergers and acquisitions. No wonder, financial stocks were the winners in the past decade.

Direxion Daily Financial Bull 3x Shares – Up 2115.3%


A dovish Fed, low rates, cheaper oil since 2014, a decently growing U.S. economy, solid job growth (in the pre-COVID era), a soaring stock market, the resultant wealth effect, and upbeat consumer confidence helped the consumer stocks, especially the retail ones.

Direxion Daily Retail Bull 3x Shares – Up 1886.6%

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


Direxion Daily Financial Bull 3X Shares (FAS): ETF Research Reports


ProShares UltraPro QQQ (TQQQ): ETF Research Reports


Direxion Daily Semiconductor Bull 3X Shares (SOXL): ETF Research Reports


Direxion Daily Retail Bull 3x Shares (RETL): ETF Research Reports


Direxion Daily Healthcare Bull 3x Shares (CURE): ETF Research Reports


To read this article on click here.


Zacks Investment Research